Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303884 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP3A4MAPTCTSKCTSS | |
| SCHEMBL6227187 | 0.78 | ALDH1A1 (0.62) | ALDH1A1CYP3A4NPSR1 | |
| SCHEMBL4302729 | 0.78 | ALDH1A1 (0.65) | ALDH1A1CYP3A4NPSR1 | |
| SCHEMBL4308169 | 0.75 | ALDH1A1 (0.61) | ALDH1A1CYP3A4NPSR1 | |
| SCHEMBL4308166 | 0.75 | ALDH1A1 (0.61) | ALDH1A1CYP3A4NPSR1 | |
| SCHEMBL4305771 | 0.75 | ALDH1A1 (0.61) | ALDH1A1CYP3A4NPSR1 | |
| SCHEMBL4305768 | 0.75 | ALDH1A1 (0.61) | ALDH1A1CYP3A4NPSR1 | |
| SCHEMBL28757481 | 0.74 | ALDH1A1 (0.64) | ALDH1A1CYP3A4NPSR1 | |
| SCHEMBL27745938 | 0.73 | CTSK (0.50) | ALDH1A1CYP3A4MAPTCTSKCTSS | |
| SCHEMBL27766765 | 0.73 | CTSK (0.50) | ALDH1A1CYP3A4MAPTCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1640361-B9 | ASYMMETRIC UREA COMPOUNDS AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUNDS BY ASYMMETRIC CONJUGATE ADDITION REACTION USING THE SAME AS CATALYST | SUMITOMO CHEMICAL CO (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-1640361-B1 | ASYMMETRIC UREA COMPOUNDS AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUNDS BY ASYMMETRIC CONJUGATE ADDITION REACTION USING THE SAME AS CATALYST | SUMITOMO CHEMICAL CO (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-7632970-B2 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20060161006-A1 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1640361-A2 | ASYMMETRIC UREA COMPOUND AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUND BY ASYMMETRIC CONJUGATE ADDITION REACTION WITH THE SAME AS CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060161006-A1 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | RAD18, UTP18, UBE2G2 | ALDH1A1 2730/4885CYP3A4 342/4885MAPT 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.